3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
19
Colonic Neoplasms
9
Pancreatic Neoplasms
8
Esophageal Neoplasms
7
Stomach Neoplasms
6
Rectal Neoplasms
5
Adenocarcinoma Of Esophagus
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Lymphoma, Large B-Cell, Diffuse
4
Cholangiocarcinoma
4
Carcinoma, Non-Small-Cell Lung
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Neoplasms
3
Endometrial Neoplasms
3
Adenocarcinoma
3
Recurrence
2
Lymphoma, Follicular
2
Lung Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Hepatocellular
2
Biliary Tract Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Small Bowel Adenocarcinoma
1
Prostatic Neoplasms
1
Interventions
tivozanib
2
durvalumab
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Gemcitabine
2
Cisplatin
2
olaparib
1
atezolizumab
1
Stents
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
Oxaliplatin
×
30 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts